After completing this activity, the participant will demonstrate the ability to:
- Discuss the limitations of currently available lipid-lowering agents and the need for novel treatment options
- Describe the mechanism of action, efficacy and safety of PCSK9 inhibitors and what differentiates them from other forms of lipid-lowering therapy
- Review the clinical trial data supporting the use of PCSK9 inhibitors to lower LDL cholesterol and ongoing outcomes trials in at-risk patients with hypercholesterolemia
- Apply current evidence-based therapies to optimize control of LDL-C in patients with hypercholesterolemia
the CMECompanion will alert you when new activities become available that are relevant to your specialty. Please take a moment to review the activity list below. We hope you find it to be valuable to your CME work.